2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123203
    CP-608039 331727-55-0 98%
    CP-608039 is a potent and selective adenosine A3 receptor agonist. CP-608039 can be used for ischemic myocardial injury research.
    CP-608039
  • HY-123254
    CCG-224406 1870843-22-3 98%
    CCG-224406 is a selective G protein-coupled receptor kinase 2 (GRK2) inhibitor with the IC50 values of 13 nM, greater than 700-fold selectivity over other GRK subfamilies, and no inhibition of ROCK1. CCG-224406 can be used for study of heart failure.
    CCG-224406
  • HY-123268
    Ro 363 74513-77-2 98%
    Ro 363, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.
    Ro 363
  • HY-123293
    UK 34787 72818-36-1 98%
    UK 34787 is a selective thromboxane synthetase inhibitor with little or no activity against cyclooygenase or prostacyclin synthetase.
    UK 34787
  • HY-123322
    PF-184298 813447-40-4 98%
    PF-184298 is a dual serotonin/noradrenaline reuptake inhibitor with IC50 of 6 nM and 21 nM, respectively.
    PF-184298
  • HY-123353
    Neladenoson dalanate 1239309-58-0 98%
    Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases.
    Neladenoson dalanate
  • HY-123356
    EMD-503982 768370-75-8 98%
    EMD-503982 is an orally available FXa inhibitor.
    EMD-503982
  • HY-123368
    Zolertine hydrochloride 7241-94-3 98%
    Zolertine hydrochloride is an α-adrenoceptor antagonist with a pKi of 6.81 in rat liver (α1B-adrenoceptors) and 6.35 in rabbit liver (α1A-adrenoceptors) membranes.
    Zolertine hydrochloride
  • HY-123427
    Transcainide 88296-62-2 98%
    Transcainide (R 54718) is an orally active antiarrhythmic agent.
    Transcainide
  • HY-123445
    AZD7009 864368-79-6 98%
    AZD7009 is a novel antiarrhythmic agrnt. AZD7009 inhibits hKv1.5 and hKv4.3/hKChIP2.2 currents with IC50s of 27.0 and 23.7 muM, respectively.
    AZD7009
  • HY-123563
    Metazosin 95549-92-1 98%
    Metazosin (Kenosin) is a potent α1 adrenoceptor blocker. Metazosin is an antihypertensive agent lowering blood pressure.
    Metazosin
  • HY-123569
    ISQ-1 hydrochloride 405165-77-7 98%
    ISQ-1 hydrochloride is an isoquinolinone (IKur) blocker with potential atrial arrhythmic activity. ISQ-1 exhibits cardiac electrophysiological characteristics similar to another structurally distinct IKur blocker previously reported from our laboratory.
    ISQ-1 hydrochloride
  • HY-123657
    RXP 407 237770-41-1 98%
    RXP 407 is a potent and selective Angiotensin-converting Enzyme (ACE) inhibitor with a Ki of 12nM.
    RXP 407
  • HY-123679
    FR168888 168620-46-0 98%
    FR168888 is an inhibitor of Na+/H+ exchange with a Ki value of 6.4 nM.
    FR168888
  • HY-123721
    Tiracizine hydrochloride 78816-67-8 98%
    Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease.
    Tiracizine hydrochloride
  • HY-123744
    PD-156707 162412-70-6 99.92%
    PD-156707 is an orally active, nonpeptide and selective Endothelin-A receptor antagonist.
    PD-156707
  • HY-124104
    Aldicarb sulfoxide 1646-87-3 98%
    Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish.
    Aldicarb sulfoxide
  • HY-124109
    TRC051384 hydrochloride 1333327-56-2 98%
    TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke.
    TRC051384 hydrochloride
  • HY-124150
    BM567 284464-77-3 98%
    BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively.
    BM567
  • HY-124153
    GNE-431 1433820-83-7 98%
    GNE-431 is a potent, selective and noncovalent “pan-BTK” inhibitor against C481R, T474I and T474Ms mutants. GNE-431 shows potency against wild-type BTK (IC50= 3.2 nM) and potency against C481S mutant (IC50= 2.5 nM). GNE-431 is proming for rasearch of haematological disorders and autoimmune diseases.
    GNE-431
Cat. No. Product Name / Synonyms Application Reactivity